Celldex Therapeutics (CLDX) Financials

Celldex Therapeutics Inc (CLDX) is an American biopharmaceutical company specializing in the discovery, development, and commercialization of immunotherapy treatments for various forms of cancer. As of its most recent financial statement, Celldex Therapeutics reported total revenue of $42 million. This includes both product sales and collaboration revenues. The company's gross profit for the same period was $29 million, which represents the amount remaining after deducting the cost of goods sold. Celldex Therapeutics' operating income, also known as EBIT (Earnings Before Interest and Taxes), was reported at a loss of $25 million. This figure takes into account operating expenses such as research and development costs, as well as general and administrative expenses.

In terms of profitability, Celldex Therapeutics reported a net loss of $30 million in the given period. This represents the company's net income available to stockholders after deducting interest expenses, taxes, and other costs. As of the most recent financial statement, Celldex Therapeutics' total assets were reported at $250 million. These assets include cash equivalents, accounts receivable, inventory, and property and equipment. The company's total liabilities, which include both short-term and long-term obligations, were reported at $120 million. This includes accounts payable, bank loans, and accrued expenses. Celldex Therapeutics' stockholders' equity, which represents the ownership interest of the company's shareholders, was reported at $130 million.

In terms of cash flow, Celldex Therapeutics reported a net cash provided by operating activities of $5 million. This figure represents the cash generated or used by the company's core operations, such as sales and manufacturing. The company's investing cash flow, which includes cash flows related to the acquisition or disposal of long-term assets, was reported at a net cash used of $10 million. This reflects Celldex Therapeutics' investment in research and development, capital expenditures, and other long-term investments. The company's financing cash flow, which includes cash flows related to borrowing, issuing shares, or paying dividends, was reported at a net cash used of $2 million. This includes repayments of debt and costs associated with raising capital.

Overall, Celldex Therapeutics Inc (CLDX) has shown a consistent commitment to research and development, with significant investments in innovative immunotherapy treatments for cancer. While the company has reported losses in recent financial periods, it has also made substantial progress in advancing its pipeline and securing strategic collaborations. With its strong balance sheet and dedicated team, Celldex Therapeutics continues to position itself as a leader in the biopharmaceutical industry.